SIETES :: 93212 citas

Resultados de la búsqueda por FARMACOCINÉTICA REFINAR BÚSQUEDA

21.

Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. BIP31.fr 2017;24:60. [Ref.ID 102182]

22.

Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]

23.

Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLOS Medicine 2017:10 de octubre. [Ref.ID 102114]

24.

Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]

25.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

26.

Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]

27.

Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]

28.

Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699. [Ref.ID 102018]

29.

Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]

30.

Russo EB. Cannabidiol claims and misconceptions. Trends Pharmacol Sci 2017;38:198-201. [Ref.ID 101988]

31.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]

32.

Nalla P, Dacruz TA, Obuobie K. Tiredness in a patient treated with itraconazole. BMJ 2017;356:i6819. [Ref.ID 101383]

33.

Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ 2016;354:8 de octubre. [Ref.ID 100796]

34.

Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 2016;354:i5014. [Ref.ID 100795]

35.

Geschwind MD, Paras N. Deutetrabenazine for treatment of Chorea in Huntington disease. JAMA 2016;316:33-5. [Ref.ID 100619]

36.

Wang Y, Zhao X, Lin J, Johnston C, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, for the CHANCE Investigators. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016;316:70-8. [Ref.ID 100516]

37.

Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease. A randomized clinical trial. JAMA 2016;316:40-50. [Ref.ID 100515]

38.

Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]

39.

Anónimo. FDA approves Epclusa for treatment of chronic hepatitis C virus infection. U.S. Food and Drug Administration 2016:28 de junio. [Ref.ID 100447]

40.

Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]